279 related articles for article (PubMed ID: 22221000)
1. Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.
Yang LP
Drugs; 2012 Jan; 72(2):229-48. PubMed ID: 22221000
[TBL] [Abstract][Full Text] [Related]
2. Vildagliptin: a review of its use in type 2 diabetes mellitus.
Keating GM
Drugs; 2010 Nov; 70(16):2089-112. PubMed ID: 20964454
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
Scheen AJ; Charpentier G; Ostgren CJ; Hellqvist A; Gause-Nilsson I
Diabetes Metab Res Rev; 2010 Oct; 26(7):540-9. PubMed ID: 20824678
[TBL] [Abstract][Full Text] [Related]
4. Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus.
Kania DS; Gonzalvo JD; Weber ZA
Clin Ther; 2011 Aug; 33(8):1005-22. PubMed ID: 21802144
[TBL] [Abstract][Full Text] [Related]
5. Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus.
Karyekar CS; Ravichandran S; Allen E; Fleming D; Frederich R
Clin Interv Aging; 2013; 8():419-30. PubMed ID: 23626461
[TBL] [Abstract][Full Text] [Related]
6. Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.
Schwartz SL
Ann Med; 2012 Mar; 44(2):157-69. PubMed ID: 22132773
[TBL] [Abstract][Full Text] [Related]
7. Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes.
Rosenstock J; Gross JL; Aguilar-Salinas C; Hissa M; Berglind N; Ravichandran S; Fleming D
Diabet Med; 2013 Dec; 30(12):1472-6. PubMed ID: 23802840
[TBL] [Abstract][Full Text] [Related]
8. Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.
Neumiller JJ; Campbell RK
Am J Health Syst Pharm; 2010 Sep; 67(18):1515-25. PubMed ID: 20811029
[TBL] [Abstract][Full Text] [Related]
9. Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin.
Karyekar CS; Frederich R; Ravichandran S
Int J Clin Pract; 2013 Aug; 67(8):759-67. PubMed ID: 23795975
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.
Karyekar C; Donovan M; Allen E; Fleming D; Ravichandran S; Chen R
Postgrad Med; 2011 Jul; 123(4):63-70. PubMed ID: 21680990
[TBL] [Abstract][Full Text] [Related]
11. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
Jadzinsky M; Pfützner A; Paz-Pacheco E; Xu Z; Allen E; Chen R;
Diabetes Obes Metab; 2009 Jun; 11(6):611-22. PubMed ID: 19515181
[TBL] [Abstract][Full Text] [Related]
12. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial.
Göke B; Gallwitz B; Eriksson J; Hellqvist A; Gause-Nilsson I;
Int J Clin Pract; 2010 Nov; 64(12):1619-31. PubMed ID: 20846286
[TBL] [Abstract][Full Text] [Related]
13. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.
Barnett AH; Charbonnel B; Donovan M; Fleming D; Chen R
Curr Med Res Opin; 2012 Apr; 28(4):513-23. PubMed ID: 22313154
[TBL] [Abstract][Full Text] [Related]
14. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Scheen AJ
Diabetes Metab; 2012 Apr; 38(2):89-101. PubMed ID: 22197148
[TBL] [Abstract][Full Text] [Related]
15. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Tahrani AA; Piya MK; Barnett AH
Adv Ther; 2009 Mar; 26(3):249-62. PubMed ID: 19330494
[TBL] [Abstract][Full Text] [Related]
16. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials.
Cook W; Minervini G; Bryzinski B; Hirshberg B
Postgrad Med; 2014 Oct; 126(6):19-32. PubMed ID: 25414932
[TBL] [Abstract][Full Text] [Related]
17. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes.
Lam S; Saad M
Cardiol Rev; 2010; 18(4):213-7. PubMed ID: 20539105
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: predictive factors of the treatment response in type 2 diabetes.
Gautier JF; Sauvanet JP
Ann Endocrinol (Paris); 2011 Sep; 72(4):287-295. PubMed ID: 21777901
[TBL] [Abstract][Full Text] [Related]
19. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION).
Schernthaner G; Durán-Garcia S; Hanefeld M; Langslet G; Niskanen L; Östgren CJ; Malvolti E; Hardy E
Diabetes Obes Metab; 2015 Jul; 17(7):630-8. PubMed ID: 25761977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
